A Phase-Ib Dose-Finding Study of the SMAC Mimetic Debio 1143 When Given in Combination With the Anti-PD-L1 Antibody Avelumab to Patients With Advanced Solid Malignancies and, in an Expansion Cohort, to Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Trial Profile

A Phase-Ib Dose-Finding Study of the SMAC Mimetic Debio 1143 When Given in Combination With the Anti-PD-L1 Antibody Avelumab to Patients With Advanced Solid Malignancies and, in an Expansion Cohort, to Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2017

At a glance

  • Drugs AT 406 (Primary) ; Avelumab
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Debiopharm
  • Most Recent Events

    • 06 Nov 2017 According to a Debiopharm media release, The trial is being conducted under a clinical collaboration agreement announced last year between Debiopharm International SA and the Merck-Pfizer Alliance.
    • 06 Nov 2017 According to a Debiopharm media release, first patient has been dosed.
    • 04 Oct 2017 Planned initiation date changed from 4 Sep 2017 to 9 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top